In a rare misfire, Regeneron scraps its RSV drug after a PhIII failure
In a rare Phase III failure, Regeneron says its late-stage antibody for RSV — suptavumab (REGN2222) — flopped in a major study which enrolled more than a thousand healthy pre-term infants.
Although researchers were able to tease out evidence of efficacy in one subgroup, they say the drug failed to significantly reduce the number of medically-attended RSV infections.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.